StreetInsider.com News Articles

Merck's Keytruda cuts disease progression risk in endometrial cancer

Mon, 26 Oct 2026 11:35:19 -0400

Merck (NYSE: MRK) announced results from the Phase 3 KEYNOTE-C93 trial showing that pembrolizumab, sold as Keytruda, as a monotherapy reduced the risk of disease progression or death by 43% compared to platinum doublet chemotherapy in patients with mismatch repair deficient (dMMR) advanced or recurrent endometrial cancer who had not previously received systemic chemotherapy or who experienced recurrence after prior adjuvant therapy.

After a median follow-up of 36.7 months, median progression-free survival (PFS) was 38.2 months for patients receiving Keytruda compared to 8.4 months for those receiving chemotherapy. The 36-month PFS rates were 52.8% and 30.0%, respectively.

A favorable trend in overall

KEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMM

Mon, 26 Oct 2026 11:35:00 -0400

KEYNOTE-C93 showed median progression-free survival (PFS) was more than four times longer for these patients treated with KEYTRUDA as monotherapy (38.2 months) compared to platinum doublet chemotherapy (8.4 months)

KEYNOTE-C93 is the first Phase 3 trial of a PD-1 inhibitor to show a statistically significant and clinically meaningful improvement in PFS as monotherapy compared to chemotherapy in these patients

Late-breaking results were selected for an official press briefing and will be presented during a Presidential Symposium session at the European Society for Medical Oncology (ESMO) Congress 2026 and published simultaneously in The Lancet

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck

KEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMM

Mon, 26 Oct 2026 11:35:00 -0400

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck

Merck drug cuts death risk by 32% in endometrial cancer trial

Mon, 26 Oct 2026 11:31:19 -0400

Merck (NYSE: MRK) announced results from its pivotal Phase 3 TroFuse-005 trial showing that sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate (ADC) developed with Kelun-Biotech, reduced the risk of death by 32% and the risk of disease progression or death by 41% compared to chemotherapy in patients with advanced or recurrent endometrial cancer who had previously received platinum-based chemotherapy and anti-PD-1/L1 immunotherapy.

At a pre-specified interim analysis with a median follow-up of 14.0 months, sac-TMT extended median overall survival (OS) by 6.9 months compared to treatment of physician's choice (19.0 months vs. 12.1 months). Median progression-free survival (PFS) was extended

Merck drug cuts death risk by 32% in endometrial cancer trial

Mon, 26 Oct 2026 11:31:19 -0400

Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometri

Mon, 26 Oct 2026 11:30:00 -0400

TroFuse-005 is the first and only global Phase 3 study of a TROP2 ADC to demonstrate improved overall survival (OS) and progression-free survival (PFS) compared to chemotherapy in these patients who have received prior platinum-based chemotherapy and anti-PD-1/L1 immunotherapy

Results from TroFuse-005 were selected for an official press briefing and will be presented during a Presidential Symposium session at the European Society for Medical Oncology (ESMO) Congress 2026 and published simultaneously in The Lancet

Based on these data, the U.S. FDA has accepted for priority review a Biologics License Application for sac-TMT for these patients

RAHWAY,

Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometri

Mon, 26 Oct 2026 11:30:00 -0400

Based on these data, the U.S. FDA has accepted for priority review a Biologics License Application for sac-TMT for these patients

RAHWAY,

Buy this large-cap pharma stock on weakness: Wells Fargo

Mon, 26 Oct 2026 09:00:00 -0400

Wells Fargo said concerns weighing on a major drugmaker's shares after detailed results from a closely watched cancer vaccine trial look overdone, recommending investors buy on weakness.

Analyst Mohit Bansal kept an Overweight rating and $165 price target on Merck (NYSE: MRK). In a flash comment, he said the data appear to exceed investor expectations, while a weaker overall survival figure "is likely driven by data immaturity."

Merck and Moderna released detailed Phase 3 results from the INTerpath-001 trial, which tested their individualized mRNA therapy intismeran autogene alongside Keytruda in patients with completely resected stage IIB-IV melanoma. The combination cut the risk

Buy this large-cap pharma stock on weakness: Wells Fargo

Mon, 26 Oct 2026 09:00:00 -0400

Wells Fargo said concerns weighing on a major drugmaker's shares after detailed results from a closely watched cancer vaccine trial look overdone, recommending investors buy on weakness.

Buy this large-cap pharma stock on weakness: Wells Fargo

Mon, 26 Oct 2026 09:00:00 -0400

Wells Fargo said concerns weighing on a major drugmaker's shares after detailed results from a closely watched cancer vaccine trial look overdone, recommending investors buy on weakness.

Buy this large-cap pharma stock on weakness: Wells Fargo

Mon, 26 Oct 2026 09:00:00 -0400

Wells Fargo said concerns weighing on a major drugmaker's shares after detailed results from a closely watched cancer vaccine trial look overdone, recommending investors buy on weakness.

A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets

Mon, 26 Oct 2026 08:53:00 -0400